GPI 2A

Drug Profile

GPI 2A

Alternative Names: Anti-p24 Antisense

Latest Information Update: 07 Feb 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Viventia Biotech
  • Class Antisense oligonucleotides; Antivirals
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 26 Feb 1999 Suspended-I for HIV infections treatment in Canada (IV-infusion)
  • 11 Nov 1998 A phase I study has been added to the adverse effects section
  • 15 Dec 1997 Phase-I clinical trials for HIV infections treatment in Canada (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top